All In Biotech

Investigational drug · Phase 2

CIT-013

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hidradenitis Suppurativa (HS), Rheumatoid Arthritis.

Phase 2

Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

2

1 still active

All registered trials

4

Any phase or sponsor naming "CIT-013"

First trial start

2025

Jul 29, 2025

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "CIT-013", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Hidradenitis Suppurativa (HS)
  • Rheumatoid Arthritis

Approved drugs for the same conditions: Rheumatoid arthritis · Hidradenitis suppurativa · Immunology and inflammation

Largest trials

Live from ClinicalTrials.gov: studies naming "CIT-013" as an intervention, largest first.

All trials
  • A Study With CIT-013 in HS PatientsPivotal-lookingActive, not recruiting

    Citryll BVIndustry

    NCT06993233 · 108 participants · Start Oct 31, 2025 · Primary completion Apr 2027

    Drug: CIT-013 high dose; CIT-013 medium dose and 1 more · For: Hidradenitis Suppurativa (HS)

    Sites: Barrie, Canada; Calgary, Canada; London, Canada · 28 sites in all

  • Citryll BVIndustry

    NCT06567470 · 96 participants · Start Jul 29, 2025 · Primary completion Jul 2, 2026

    Drug: CIT-013 low dose; CIT-013 high dose and 2 more · For: Rheumatoid Arthritis

    Sites: Leuven, Belgium; Bamberg, Germany; Berlin, Germany · 20 sites in all

  • Citryll BVIndustry

    NCT07499908 · 10 participants · Start Jun 23, 2026 · Primary completion Aug 10, 2026

    Drug: CIT-013 high dose; Placebo · For: Healthy Adult

    Sites: Groningen, Netherlands

  • Citryll BVIndustry

    NCT07147959 · 7 participants · Start Jan 15, 2026 · Primary completion Jul 15, 2026

    Drug: [89Zr]Zr-CIT · For: RA

    Sites: Nijmegen, Netherlands

Newest research

PubMed records naming it or its code names, newest first.

All 7 on PubMed

Also in development for Hidradenitis Suppurativa (HS)

  • PovorcitinibINCB054707, INCB54707Phase 312 trials

    Incyte · Hidradenitis Suppurativa (HS), NonSegmental Vitiligo, Prurigo Nodularis

  • BFB759Phase 32 trials

    Bluefin Biomedicine, Inc. · Atopic Dermatitis (AD), Hidradenitis Suppurativa (HS)

  • LT-002-158Phase 23 trials

    Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. · Atopic Dermatitis (AD), Hidradenitis Suppurativa (HS)

  • ORKA-002Phase 23 trials

    Oruka Therapeutics, Inc. · Plaque Psoriasis, Hidradenitis Suppurativa (HS)

  • CIT-013 dosePhase 22 trials

    Citryll BV · Hidradenitis Suppurativa (HS), Rheumatoid Arthritis

  • SL-325Phase 22 trials

    Shattuck Labs, Inc. · Crohn's Disease, Hidradenitis Suppurativa (HS)

  • SPY002-072SPY072Phase 22 trials

    Spyre Therapeutics, Inc. · Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis

  • TibulizumabZB-106Phase 22 trials

    Zura Bio Inc · Hidradenitis Suppurativa (HS), Systemic Sclerosis (SSc), Scleroderma

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.